HIV diagnostics offer detection of Human Immunodeficiency Virus (HIV) that causes AIDS. The diagnostics products available in the market are rapid test kits, third generation ELISAs, Western Blot and nucleic acid-based tests. The rising prevalence of HIV in Asia Pacific region has increased the demand for accurate and effective diagnostics. HIV diagnostics help in early detection and management of the infected people. The need for donor screening and disease monitoring has also fueled the need for HIV diagnostics in the region. The growing awareness regarding HIV and available treatment options have encouraged more people to opt for HIV screening.
The Asia Pacific HIV Diagnostics Market is estimated to be valued at US$ 522.5 Mn in 2024 and is expected to exhibit a CAGR of 12% over the forecast period 2023 to 2030.
Key Takeaways
Key players operating in the Asia Pacific HIV Diagnostics are Abbott Laboratories, Merck KGaA, F. Hoffmann-La Roche AG, Atomo Diagnostics, Siemens Healthineers, Inc., bioLytical Laboratories Inc., MedMira Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., and Danaher Corporation. These players are increasingly investing in the development and launch of innovative and advanced diagnostics products in the region.
The Asia Pacific region provides high growth opportunities for HIV diagnostics owing to increasing availability of public and private funding for HIV control programs. Various governments and non-profit organizations are working towards creating awareness about HIV testing and supporting diagnostics access in developing countries. Rising discretionary incomes and focus on healthcare infrastructure development will further drive market growth.
The key market players are expanding their presence across different countries in Asia Pacific to tap the business opportunities. Companies are also collaborating with regional hospitals, diagnostic centers and research institutes for knowledge sharing and capacity building. Partnerships with distributors help in expanding their sales and distribution networks in remote and rural areas.
Market Drivers
Increasing HIV prevalence and availability of reimbursement for diagnostics are major market drivers. According to UNAIDS, around 4.5 million people were living with HIV in Asia Pacific in 2021.Also, favorable government initiatives towards HIV screening and provision of subsidized diagnostics to vulnerable population boosts the market demand.
Market Restraints
Low awareness in developing nations and social stigma associated with HIV continue to hamper the market growth. Inaccessibility of HIV testing facilities in remote locations also poses challenges. Stringent regulatory approvals and insufficient skilled professionals can restrict the market expansion.
Segment Analysis
The Asia Pacific HIV diagnostics market is segmented into test type, end user, and country. The test type segment is further divided into screening tests, diagnostic tests, and others. Among these, the screening tests segment dominated the market in 2022 owing to the high adoption of HIV screening to check HIV status. This segment is anticipated to remain dominant during the forecast period due to the rising implementation of screening programs along with increasing awareness regarding HIV screening.
Global Analysis
Regionally, China accounted for the largest share of the Asia Pacific HIV diagnostics market in 2022 owing to the rising prevalence of HIV/AIDS cases and growing awareness regarding HIV diagnosis in the country. India is anticipated to grow at the fastest CAGR during the forecast period. This is attributed to increasing healthcare expenditures, rising adoption of advanced diagnostic technologies, and growing prevalence of HIV cases in the country. Abbott Laboratories, Merck KGaA, F. Hoffmann-La Roche AG, Atomo Diagnostics, Siemens Healthineers, Inc., bioLytical Laboratories Inc., MedMira Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., and Danaher Corporation are some of the key players operating in the Asia Pacific HIV diagnostics market.
No comments:
Post a Comment